RxDoctor Payments Data

Christopher Whelan, MD

Urology · Rockford, ILNPI 1275745267

Payments from drug & device makers

$3,011in general payments, 2019–2025

Across 79 payments — averaging $38.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$1K
  • Astellas Pharma US Inc$329
  • Myriad Genetic Laboratories, Inc.$280
  • Dendreon Pharmaceuticals LLC$174
  • Cook Medical LLC$139
  • AbbVie$134
  • plus $909 from 21 others

What the payments were for

  • Travel & lodging$79526%
  • Food & beverage$2,12871%
  • Education$883%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,011 in reported general payments places this provider in the 55th percentile of 550 urology providers in Illinois.

See all urology providers in Illinois

Medicare billing

Part B allowed, 2024
$237,555
Medicare patients
570
Services billed
5,109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide55$783,267
ErleadaApalutamide12$185,894
MyrbetriqMirabegron116$93,001
Tamsulosin Hcl846$11,109
Potassium Citrate ErPotassium Citrate56$4,946
Finasteride396$4,499
Solifenacin Succinate107$3,215
Oxybutynin Chloride ErOxybutynin Chloride124$2,003
NitrofurantoinNitrofurantoin Macrocrystal61$1,880
Cephalexin43$1,110
Bicalutamide18$854
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst76$791
Estradiol11$712
Dutasteride12$545
Cefdinir43$373

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$329$876,269171 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 550 urology providers in Illinois.

Other urology in Rockford

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →